DESFERAL VIALS 500MG

Active substance: DESFERRIOXAMINE MESILATE

View full screen / Print PDF » Download PDF ⇩

Transcript
DESFERAL® Vials
500 mg and 2 g

Ciba

ingredient in Desferal, is a substance called
a ‘chelating’ agent. This means that it binds
to the iron and aluminium ions in the blood
to form a complex which is then excreted
from the body.
You may have too much iron or aluminium
in your blood as a result of iron poisoning or
as a side effect of blood transfusion or
kidney dialysis. Certain illnesses can also
have the same effect.

(desferrioxamine mesilate)
Patient Information Leaflet
What you need to know about Desferal
Your doctor has decided that you need this
medicine to help treat your condition.

If the answer to any of these questions is
YES, tell your doctor or pharmacist because
Desferal might not be the right medicine
for you.
Are you taking other medicines?
Some medicines can interfere with your
treatment. Tell your doctor if you are taking
any of the following:
• prochlorperazine, a medicine used to
control vertigo or nausea and vomiting,
anxiety or schizophrenia
• erythropoietin (used to treat anaemia,
particularly in people who are on dialysis)
• Vitamin C.
Always tell your doctor about all the medicines
you are taking. This means medicines you
have bought yourself as well as medicines on
prescription from your doctor.

Desferal can also be used to test whether
you have certain anaemias or diseases
affecting the amount of iron in your blood.

Please read this leaflet carefully before
you start to take your medicine. It contains
important information. Keep the leaflet in a
safe place because you may want to read it
again. If you have any other questions, or if
there is something you don’t understand,
please ask your doctor or pharmacist.

2. Things to consider before you take
Desferal

Some people MUST NOT take Desferal.
Talk to your doctor if:
• you think you may be allergic to Desferal
or desferrioxamine.

This medicine has been prescribed for you.
Never give it to someone else. It may not
be the right medicine for them even if their
symptoms seem to be the same as yours.

You should also ask yourself these
questions before taking Desferal:
• Are you pregnant or planning to become
pregnant? If you become pregnant while
you are being treated with Desferal you
must tell your doctor straight away.
• Are you breast feeding?
• Do you have any kidney problems or are
you on dialysis?
• Do you have a heart condition?
• Do you have the blood condition
thalassaemia?
• Is Desferal going to be given to a child
under the age of 3 years? If it is, the
doctor may want to monitor the child’s
growth regularly to make sure it is not
being affected by the Desferal.
• Has your doctor told you that you have
hyperparathyroidism (a condition
resulting in excess calcium in the blood
and problems with the bones)?
• Has your doctor told you that aluminium
has affected your nerves? If so you may
be given a dose of clonazepam before
you are given Desferal.

If any of the side effects gets serious, or if
you notice any side effects not listed in this
leaflet, please tell your doctor or pharmacist.
This medicine will be called Desferal
throughout this leaflet
In this leaflet:
1. What Desferal is and what it’s used for
2. Things to consider before you take Desferal
3. How to take Desferal
4. Possible side effects
5. How to store Desferal
6. Further information

1. What Desferal is and what it’s
used for

Desferal is an injection used to remove
excess iron or aluminium from your blood.
Desferrioxamine mesilate, the active

Will there be any problems with driving
or using machinery?
Desferal can make you feel dizzy or drowsy. It
can also affect your vision or hearing. You
must not drive, operate machinery or do
anything else which requires concentration
until you know how your medicine affects you.
Other special warnings
• Medical check-ups while you are
using Desferal
If you use Desferal for a long time or you have
kidney problems and are on dialysis, your
doctor may want to give you regular eye tests
and hearing tests. This is because Desferal
can affect your vision and your hearing. These
tests are usually done every 3 months.
• Children
In children under the age of 3 years high
doses of Desferal may affect growth.
Regular checks on body weight and height
are, therefore, recommended in children
using Desferal. These checks are usually
done every 3 months.

2150614_GB_p5_LFT.indd 1

Brewery House,
The Maltings,
Silvester Street
Kingston-Upon-Hull
HU1 3HA
Tel: +44 (0) 1482 973000

x Yes
Live Text:
/
No
WO:
1167890
Comp. Description: Leaflet DESFERAL LYVI GB
Comp. Number New: 2150614 GB
Comp. Number Old: 2139243 GB
Format/Dimension: 594 x 210mm
Tech. Drawing No.: 800.4.9008/03

/

Both

Production Site:
CTM:
Printing Colours:

Stein
Martin, Rosalyn
Black

Technical Colours: Cutting
Dimensions

Minimum Font Size: 10.0pt
Font Type: News Gothic, Helvetica Neue LT Pro
15/08/2014

The dose that you need will depend on why
you have to take Desferal. Your doctor will
work out exactly how much Desferal you
need. This is especially important if you
have low serum ferritin levels or acute iron
intoxication.

3. How to take Desferal

The usual doses and ways of taking
Desferal are as follows:

The doctor will have decided what dose of
Desferal you need and when you should
take it. The dose will be on the pharmacist’s
label. Check the label carefully. If you are
not sure, ask your doctor or pharmacist.
A doctor or nurse may prepare your injection
for you, or you may be taught how to do this
yourself. The Desferal powder should be
dissolved in the ‘water for injection’ that your
pharmacist has given you.
Treatment with the solution should start
within 3 hours of the vial being
reconstituted. If the solution has been
prepared under sterile conditions
(for instance in a hospital), it may be stored
at room temperature (25oC or below) for up
to 24 hours before being used. Any unused
Desferal injection should be thrown away.
Ways in which Desferal can be given
Desferal can be given in different ways,
for example:
• By injection into a muscle. This is called
being given intramuscularly.
• By injection into a vein. This is called
being given intravenously. It should be
given slowly over a period of time rather
than all in one go. This is called a slow
infusion.
• By injection under your skin. This is called
being given subcutaneously. It may be
given over a period of time using a
special pump. This is called an infusion.
• By injection into the peritoneum
(the membrane that lines the abdominal
cavity and forms the outer coating of the
abdominal organs). This is called
intraperitoneal administration.

• Iron Poisoning Treatment
To treat iron poisoning Desferal is usually
given intravenously (injected into the vein).
The recommended dose is 15 mg/kg body
weight every hour. This may be reduced
after 4 to 6 hours. The maximum
recommended dose is 80 mg/kg body
weight every 24 hours.
Desferal may also be given intramuscularly
(injected into the muscle). The
recommended dose if Desferal is given like
this is 2 g for an adult or 1 g for a child.
This is usually given in a single injection.
• Iron Overload Treatment
Your doctor will work out exactly how much
Desferal you will need. This will depend on
how much extra iron you have in your body.
Desferal is usually given subcutaneously
(a slow injection under the skin). It can
sometimes be given intramuscularly
(injected into the muscle) though.
The dose is usually between
20 and 60 mg/kg body weight. It is usually
given between 5 and 7 times a week,
depending on how much extra iron you have
got in your body. In children under 3 years
of age the average daily dose is not usually
more than 40 mg/kg.

Information for the healthcare
professional

Special Precautions for Storage
Vial: Store below 25°C.
Reconstituted solution : Single use only.
The product should be used immediately
after reconstitution (commencement of
treatment within 3 hours). When
prepared under validated aseptic
conditions the reconstituted solution may
be stored for a maximum of 24 hours at
room temperature (25°C or below) before
administration. If not used immediately,
in-use storage times and conditions prior
to administration are the responsibility of
the user. Unused solution should be
discarded.
Therapeutic Indications
Treatment for chronic iron overload.
Treatment for acute iron poisoning.
For the diagnosis of iron storage disease
and certain anaemias.
Aluminium overload - In patients on
maintenance dialysis for end stage renal
failure where preventative measures
(e.g. reverse osmosis) have failed and
with proven aluminium-related bone
disease and/or anaemia, dialysis
encephalopathy; and for diagnosis of
aluminium overload.

• Aluminium Overload Treatment
Desferal is usually given by slow
intravenous injection.

Posology and Method of Administration
Desferal may be administered
parenterally.

The exact dose of Desferal that you need
will depend on how much extra aluminium
you have in your body. Your doctor will do
tests to work this out.

For parenteral administration:
The drug should preferably be employed
in the form of a 10% solution,
e.g. 500 mg: by dissolving the contents

of one 500mg vial in 5ml of water for
injection or 2 g: by dissolving the
contents of one 2 g vial in 20 ml of water
for injection. When administered
subcutaneously the needle should not be
inserted too close to the dermis. The
10% Desferal solution can be diluted
with routinely employed infusion
solutions (saline, glucose, dextrose or
dextrose-saline), although these should
not be used as solvent for the dry
substance. Dissolved Desferal can also
be added to dialysis fluid and given
intraperitoneally to patients on
continuous ambulatory peritoneal
dialysis (CAPD) or continuous cyclic
peritoneal dialysis (CCPD).
Only clear pale yellow Desferal solutions
should be used. Opaque, cloudy or
discoloured solutions should be discarded.
Heparin is pharmaceutically incompatible
with Desferal solutions.
Treatment of acute iron poisoning
Dosage:
The continuous intravenous administration
of Desferal is the preferred route and the
recommended rate for infusion is 15 mg/kg
per hour and should be reduced as soon as
the situation permits, usually after
4 to 6 hours so that the total intravenous
dose does not exceed a recommended
80 mg/kg in any 24 hour period.
However, if the option to infuse
intravenously is not available and if the
intramuscular route is used the normal
dosage is 2 g for an adult and 1 g for a
child, administered as a single
intramuscular dose.
Chronic Iron Overload
Dose:
The lowest effective dose should be used.
The average daily dose will probably lie

between 20 and 60 mg/kg/day. Patients
with serum ferritin levels of < 2000 ng/mL
should require about 25 mg/kg/day, and
those with levels between
2000 and 3000 ng/mL about 35 mg/kg/day.
Higher doses should only be employed if the
benefit for the patient outweighs the risk of
unwanted effects.
Patients with higher serum ferritin may
require up to 55 mg/kg/day. It is
inadvisable to regularly exceed an
average daily dose of 50 mg/kg/day
except when very intensive chelation is
needed in patients who have completed
growth. If ferritin values fall below
1000 ng/mL, the risk of Desferal toxicity
increases; it is important to monitor
these patients particularly carefully and
perhaps to consider lowering the total
weekly dose.
To assess the chelation therapy, 24 hour
urinary iron excretion should initially be
monitored daily. Starting with a dose of
500 mg daily the dose should be raised
until a plateau of iron excretion is
reached. Once the appropriate dose has
been established, urinary iron excretion
rates can be assessed at intervals of a
few weeks.
Mode of administration:
Slow subcutaneous infusion using a
portable, light-weight, infusion pump over a
period of 8-12 hours is effective and
particularly convenient for ambulant
patients. It may be possible to achieve a
further increase in iron excretion by infusing
the same daily dose over a 24 hour period.
Desferal should normally be used with the
pump 5-7 times a week.
Since the subcutaneous infusions are more
effective, intramuscular injections are given
only when subcutaneous infusions are not
feasible.

Desferal can be administered by intravenous
infusion during blood transfusion.
The Desferal solution should not be put
directly into the blood bag but may be
added to the blood line by means of a “Y”
adaptor located near to the venous site of
injection. The patient’s pump should be
used to administer Desferal as usual.
Patients and nurses should be warned
against accelerating the infusion, as an
intravenous bolus of Desferal may lead to
flushing, hypotension and acute collapse
(see section 4.4 Special warnings and
special precautions for use).
Continuous intravenous infusion is
recommended for patients incapable of
continuing subcutaneous infusions and
in those who have cardiac problems
secondary to iron overload. 24 hour
urinary iron excretion should be
measured regularly where intensive
chelation (i.v.) is required, and the dose
adjusted accordingly. Implanted
intravenous systems can be used when
intensive chelation is carried out.
Care should be taken when flushing the line
to avoid the sudden infusion of residual
Desferal which may be present in the dead
space of the line, as this may lead to
flushing; hypotension and acute collapse
(see section 4.4 Special warnings and
special precautions for use).
Diagnosis of iron storage disease and
certain anaemias
Desferal is administered as 500 mg
intramuscular injection. Urine is then
collected for a period of 6 hours and its iron
content determined.
Excretion of 1-1.5 mg (18-27 micro mol)
of iron during this 6-hour period is
suggestive of iron overload; values

greater than 1.5 mg (27 micro mol) can
be regarded as pathological.
Treatment for aluminium overload in
patients with end stage renal failure
Adults and children:
Patients on maintenance haemodialysis
or haemofiltration: 5 mg/kg once a week.
Patients with post-desferrioxamine test
serum aluminium levels up to
300 ng/mL: Desferal should be given as
a slow i.v. infusion during the last
60 minutes of a dialysis session
(to reduce loss of free drug in the
dialysate). Patients with a
post-desferrioxamine test serum
aluminium value above 300 ng/ml:
Desferal should be administered by slow
i.v. infusion 5 hours prior to the dialysis
session.
Four weeks after the completion of a
three month course of Desferal treatment
a Desferal infusion test should be
performed, followed by a second test
1 month later. Serum aluminium
increases of less than 50ng/mL above
baseline measured in 2 successive
infusion tests indicate that further
Desferal treatment is not necessary.
Patients on CAPD or CCPD:
5 mg/kg once a week prior to the final
exchange of the day. It is recommended
that the intraperitoneal route be used in
these patients. However, Desferal can also
be given i.m., by slow infusion i.v. or s.c.
Diagnosis of aluminium overload in
patients with end stage renal failure
A Desferal infusion test is recommended in
patients with serum aluminium levels
> 60ng/mL associated with serum ferritin
2150614 GB
levels >100 ng/mL.

15/08/2014 13:14

The Maltings

Proof Number: 5
Braille:

• X-rays or scans
The results may be affected by treatment
with Desferal. Make sure that the doctor or
nurse knows that you are being treated with
Desferal if an X-ray or scan is suggested.

Jed Carter

! P LEASE TU R N OV E R P R I N T I N G O N !
518266_1

Just before starting the haemodialysis
session, a blood sample is taken to
determine the baseline level serum
aluminium level.

Treatment with Desferal by the intravenous
route should only be administered in the
form of slow infusions. Rapid intravenous
infusion may lead to hypotension and shock
(e.g. flushing, tachycardia, collapse and
urticaria).

During the last 60 minutes of the
haemodialysis session a 5 mg/kg dose is
given as a slow intravenous infusion.

Desferal should not be administered s.c. in
concentrations and/or doses higher than
those recommended as local irritation at
the site of administration may occur more
frequently.

At the start of the next haemodialysis
session (i.e. 44 hours after the
aforementioned Desferal infusion) the
second blood sample is taken to determine
the serum aluminium level once more.

Patients suffering from iron overload are
particularly susceptible to infection.
There have been reports of Desferal
promoting some infections such as
Yersinia enterocolitica and Y.
pseudotuberculosis. If patients develop
fever with pharyngitis, diffuse abdominal
pain or enteritis/enterocolitis, Desferal
therapy should be stopped, and
appropriate treatment with antibiotics
should be instituted. Desferal therapy
may be resumed once the infection has
cleared.

Use in the elderly
No special dosage regime is necessary but
concurrent renal insufficiency should be
taken into account.
Contraindications
Hypersensitivity to desferrioxamine mesilate
unless the patients can be desensitised.
Special Warnings and Precautions and
Interactions
Desferal should be used with caution in
patients with renal impairment since the
metal complexes are excreted via the
kidneys. In these patients, dialysis will
increase the elimination of chelated iron
and aluminium.

In patients , receiving Desferal for
aluminium and/or iron overload there
have been rare reports of mucormycosis
(a severe fungal infection), some with
fatal outcome. If any characteristic signs
or symptoms occur Desferal treatment
should be discontinued, mycological
tests carried out and appropriate
treatment immediately instituted.
Mucormycosis has been reported to
occur in dialysis patients not receiving
Desferal, thus no causal link with the use
of the drug has been established.

Used alone Desferal may exacerbate
neurological impairment in patients with
aluminium-related encelphalopathy. This
deterioration (manifest as seizures) is
probably related to an acute increase in
brain aluminium secondary to elevated
circulating levels. Pretreatment with
clonazepam has been shown to afford
protection against such impairment. Also,
treatment of aluminium overload may result
in decreased serum calcium and
aggravation of hyperparathyroidism.

Disturbances of vision and hearing have
been reported during prolonged Desferal
therapy. In particular, this has occurred
in patients on higher than recommended
therapy or in patients with low serum
ferritin levels. Patients with renal failure

who are receiving maintenance dialysis
and have low ferritin levels may be
particularly prone to adverse reactions,
visual symptoms having been reported
after single doses of Desferal. Therefore,
ophthalmological and audiological tests
should be carried out both prior to the
institution of long-term therapy with
Desferal and at 3-monthly intervals
during treatment. By keeping the ratio of
the mean daily dose (mg/kg of Desferal)
divided by the serum ferritin (micro g/L)
below 0.025 the risk of audiometric
abnormalities may be reduced in
thalassaemia patients. A detailed
ophthalmological assessment is
recommended (visual field
measurements, fundoscopy, and colour
vision testing using pseudoisochromatic
plates and the Farnsworth D-15 colour
test, slit lamp investigation, visual
evoked potential studies).
If disturbances of vision or hearing do
occur, treatment with Desferal should be
stopped. Such disturbances are usually
reversible. If Desferal therapy is
re-instituted later at a lower dosage, close
monitoring of ophthalmological/auditory
function should be carried out with due
regard to the risk-benefit ratio.
The use of inappropriately high doses of
Desferal in patients with low ferritin levels
or young children (<3 years at
commencement of treatment) has also
been associated with growth retardation;
dose reduction has been found to restore
the growth rate to pretreatment levels in
some cases. Three monthly checks on body
weight and height are recommended in
children.
Growth retardation if associated with
excessive doses of Desferal must be
distinguished from growth retardation

2150614_GB_p5_LFT.indd 2

Brewery House,
The Maltings,
Silvester Street
Kingston-Upon-Hull
HU1 3HA
Tel: +44 (0) 1482 973000

x Yes
Live Text:
/
No
WO:
1167890
Comp. Description: Leaflet DESFERAL LYVI GB
Comp. Number New: 2150614 GB
Comp. Number Old: 2139243 GB
Format/Dimension: 594 x 210mm
Tech. Drawing No.: 800.4.9008/03

/

Both

Production Site:
CTM:
Printing Colours:

Stein
Martin, Rosalyn
Black

Technical Colours: Cutting
Dimensions

Minimum Font Size: 10.0pt
Font Type: News Gothic, Helvetica Neue LT Pro
15/08/2014

Acute respiratory distress syndrome has
been described following treatment with
excessively high i.v. doses of Desferal in
patients with acute iron intoxication, and
also in thalassaemic patients
(see section 4.8 Undesirable effects).
The recommended daily doses should
therefore not be exceeded.
It should be noted that desferrioxamine
will affect aluminium levels and may
necessitate some dosage adjustment of
erythropoietin if co-prescribed.
Interactions with other Medicaments
and other forms of Interaction
Oral administration of vitamin C (up to a
maximum of 200 mg daily, given in
divided doses) may serve to enhance
excretion of the iron complex in response
to Desferal; larger doses of vitamin C fail
to produce an additional effect.
Monitoring of cardiac function is
indicated during such combined therapy.
Vitamin C should be given only if the
patient is receiving Desferal regularly
and should not be administered within
the first month of Desferal therapy. In
patients with severe chronic iron-storage
disease undergoing combined treatment
with Desferal and high doses of vitamin
C (more than 500 mg daily) impairment
of cardiac function has been
encountered; this proved reversible when
the vitamin C was withdrawn. Vitamin C
supplements should not, therefore, be
given to patients with cardiac failure.

Desferal should not be used in
combination with prochlorperazine
(a phenothiazine derivative) since
prolonged unconsciousness may result.
Gallium67 imaging results may be distorted
because of the rapid urinary excretion of
Desferal-bound radiolabel. Discontinuation
of Desferal 48 hours prior to scintigraphy is
advised.

If you are on dialysis, the usual dose of
Desferal is 5 mg/kg body weight. This is
normally given once a week. When you are
given your Desferal will depend on how
much extra aluminium you have in your
body. It will either be given during the last
60 minutes of your dialysis or 5 hours
before your dialysis starts.

What if you have had too much Desferal?
(Overdose)
If you think you have either been given or
have taken too much Desferal tell your doctor
or nurse straight away. If you think you have
either been given it or have taken it too often,
also tell your doctor or nurse straight away.

If you are on peritoneal dialysis (CAPD or
CCPD), the usual dose of Desferal is, again,
5 mg/kg body weight. This is normally given
once a week. Usually the Desferal is mixed
with the fluid in your dialysis bag. However,
it can also be given by any of the other
ways listed above.

What if you miss a dose of Desferal?
If you miss one of your appointments, please
let your doctor or nurse know immediately.

• Testing to see if you have got too
much iron in your body
Desferal is usually given intramuscularly
(injected into a muscle). The usual dose is
500 mg. After you have had your Desferal,
your doctor or nurse will probably want you
to collect urine samples for about 6 hours.
They will then do tests on your urine to see
how much iron is in it.
• Testing to see if you have got too
much aluminium in your body if you
are on dialysis
Your doctor or nurse will probably take a
blood sample from you before you are given
Desferal. This will be taken just before your
dialysis. Tests will be done on the blood to
see how much aluminium is in it.
The usual dose of Desferal is 5 mg/kg body
weight. It is usually given by slow
intravenous infusion (slow injection into a
vein) during the last hour of dialysis.
Another blood test will probably be taken
before your next session of haemodialysis to
check how much aluminium is in your blood.
• Use in older patients
Desferal is used in older patients at the
same doses as for other adults.

4. Possible side effects

Most people who are prescribed Desferal
will benefit from using it. As with all other
medicines though, it can cause side effects
in some people.
Do not be alarmed by this list of possible side
effects. You may not experience any of them.
Your urine may turn a reddish-brown colour.
This is because there is more iron in your
urine. This is usually nothing to worry
about, but if you are worried you should talk
to your doctor or nurse.
Some side effects can be serious
Stop taking Desferal and tell your doctor
straight away if you notice:
• Bronchospasm or tightness of chest
with wheezing or coughing and difficulty
in breathing.
• If you feel faint (you might have low
blood pressure), have a rash, or
experience itching, difficulty breathing or
facial and throat swelling. These might
be the result of an allergic reaction
which is very rare (likely to affect fewer
than 1 in 10,000 patients).
• If you notice severe decrease of urine
output (sign of kidney problem) or
experience convulsion (reported mainly in
patients on dialysis). Those side effects
were reported with unknown frequency.

Important information if you get an
infection while you are taking Desferal
If you start to feel feverish with a sore
throat or stomach pains, or general
discomfort or develop shortness of breath
while you are taking Desferal, you must
seek medical advice immediately. This is
because people who have iron or aluminium
overload are more vulnerable to certain
types of infection. If you get an infection
your doctor may want you to do some tests
and give you some medicines to treat the
infection. You may also have to stop using
Desferal until any infections clear up.
It is very common (more than 10% of
people) to develop pain, swelling, redness,
a rash, itch or scabbing at the Desferal
injection site. Less frequently blisters and a
burning sensation might be experienced.
Aching muscles or joints in the arms or legs
is also very common.
The side effects listed below have also
been reported.
Up to 1 in 10 people have experienced:
Headache, nausea (feeling sick) or fever
Itchy rash
Changes in their bones, slowing down of
growth (especially in children under 3).
Up to 1 in 100 people have experienced:
Vomiting, stomach pains
Asthma
Problems with their ears such as tinnitus
and deafness.
Up to 1 in 1,000 people have
experienced:
Problems with their eyes such as blurred
vision, impaired or loss of vision, not being
able to see colours as well (colour
blindness), not being able to see at night
(night blindness), blind spots, changes in
the retina, cataracts (cloudy lenses),
cloudiness on the front of the eye (or cornea)

Low blood pressure (light headedness,
dizziness, faintness). This can happen if
Desferal is not given correctly.
Increased risk of getting certain infections.
Up to 1 in 10,000 people have experienced:
Skin rash covering most of the body
A serious condition which causes severe
breathing problems called Acute
Respiratory Distress Syndrome
Diarrhoea
Changes in the blood which can make you
look pale or cause tiredness, headaches,
nosebleeds, dizziness or being short of
breath when exercising. You might also get
more frequent viral infections (fever, chills,
sore throat or mouth ulcers), or find that you
bleed or bruise more easily than normal.
Stomach and gut infections.
Other effects such as dizziness, loss of
feeling in their hands, feet, arms or legs,
numbness or tingling (pins and needles).
In patients on dialysis: personality changes,
headache, confusion, paralysis of part or all
of the body, stiff neck, abnormal, speech
and eye movements.
Frequency not known (cannot be
estimated from the available data).
Muscle spasms
Abnormal liver or renal function test results

If your doctor tells you to stop taking
Desferal, please take any unused vials back
to your pharmacist to be destroyed. Do not
throw them away with your normal
household water or waste. This will help to
protect the environment.

6. Further information

Desferal is available in clear glass vials
containing either 500 mg or 2 g of
desferrioxamine mesilate. This is a white or
off-white powder.
Packs contain either ten 500 mg vials or
one 2 g vial.
The product licence holder is Novartis
Pharmaceuticals UK Limited, trading as
Ciba Laboratories, Frimley Business Park,
Frimley, Camberley, Surrey, GU16 7SR,
England.
Desferal is made by Novartis Pharma AG,
Postfach 4332, Stein, Switzerland.
The manufacturer responsible for the
release on to the market is Novartis
Pharmaceuticals UK Limited, Frimley
Business Park, Frimley, Camberley, Surrey,
GU16 7SR, United Kingdom.
This leaflet was revised in April 2014.

If any of the symptoms become
troublesome, or if you notice anything else
not mentioned here, please go and see
your doctor or check with your pharmacist.

If you would like any more information, or
would like the leaflet in a different format,
please contact Medical Information at
Novartis Pharmaceuticals UK Ltd,
telephone number 01276 698370.

5. How to store Desferal

DESFERAL is a registered Trade Mark

The vials of Desferal powder before they are
made up into the injection should be stored
below 25°C.

Copyright Novartis Pharmaceuticals UK
Limited

Each vial is for single use only.
Keep out of the reach and sight of children.
Do not use Desferal after the expiry date
which is printed on the outside of the pack.

2150614 GB

15/08/2014 13:14

The Maltings

Proof Number: 5
Braille:

from iron overload. Growth retardation
from Desferal use is rare if the dose is
kept below 40 mg/kg; if growth
retardation has been associated with
doses above this value, then reduction of
the dose may result in return in growth
velocity, however, predicted adult height
is not attained.

Jed Carter

! P LEASE TU R N OV E R P R I N T I N G O N !
518266_1

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web3)